BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 16378990)

  • 1. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.
    Ito Y; Kondo E; Demachi-Okamura A; Akatsuka Y; Tsujimura K; Tanimoto M; Morishima Y; Takahashi T; Kuzushima K
    J Virol; 2006 Jan; 80(2):883-90. PubMed ID: 16378990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
    Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
    J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells.
    Sun Y; Sijts AJ; Song M; Janek K; Nussbaum AK; Kral S; Schirle M; Stevanovic S; Paschen A; Schild H; Kloetzel PM; Schadendorf D
    Cancer Res; 2002 May; 62(10):2875-82. PubMed ID: 12019167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Processing of two latent membrane protein 1 MHC class I epitopes requires tripeptidyl peptidase II involvement.
    Diekmann J; Adamopoulou E; Beck O; Rauser G; Lurati S; Tenzer S; Einsele H; Rammensee HG; Schild H; Topp MS
    J Immunol; 2009 Aug; 183(3):1587-97. PubMed ID: 19587004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers.
    Benninger-Döring G; Pepperl S; Deml L; Modrow S; Wolf H; Jilg W
    Virology; 1999 Nov; 264(2):289-97. PubMed ID: 10562493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
    Wagner HJ; Sili U; Gahn B; Vigouroux S; Huls MH; Xie W; Vignali D; Brenner MK; Heslop HE; Rooney CM
    Cytotherapy; 2003; 5(3):231-40. PubMed ID: 12850791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of the immunotherapeutic potential of a novel T cell epitope in the Epstein-Barr virus latent membrane protein 2.
    Lalonde A; Avila-Cariño J; Caruso M; de Campos-Lima PO
    Virology; 2007 May; 361(2):253-62. PubMed ID: 17207511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of T-cell immunity against Epstein-Barr virus-associated tumors by means of adenovirally transduced dendritic cells.
    Sun H; Yao K; Chen Y; Zhou F
    Chin Med J (Engl); 2004 Oct; 117(10):1558-63. PubMed ID: 15498383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.
    Turcanová V; Höllsberg P
    J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
    Gavioli R; Vertuani S; Masucci MG
    Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
    Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein.
    Gileadi U; Moins-Teisserenc HT; Correa I; Booth BL; Dunbar PR; Sewell AK; Trowsdale J; Phillips RE; Cerundolo V
    J Immunol; 1999 Dec; 163(11):6045-52. PubMed ID: 10570292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
    Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
    Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation.
    Basler M; Lauer C; Moebius J; Weber R; Przybylski M; Kisselev AF; Tsu C; Groettrup M
    J Immunol; 2012 Aug; 189(4):1868-77. PubMed ID: 22772448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].
    Zhang NH; Zhang XS; Li J; Zhang RH; Gao YF; Zeng MS
    Ai Zheng; 2006 May; 25(5):566-9. PubMed ID: 16687075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies.
    Micheletti F; Guerrini R; Formentin A; Canella A; Marastoni M; Bazzaro M; Tomatis R; Traniello S; Gavioli R
    Eur J Immunol; 1999 Aug; 29(8):2579-89. PubMed ID: 10458773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of locus-specific human lymphocyte antigen class I expression in Epstein-Barr virus-associated gastric cancer: implication for viral-induced immune evasion.
    Dutta N; Gupta A; Mazumder DN; Banerjee S
    Cancer; 2006 Apr; 106(8):1685-93. PubMed ID: 16541432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.